vs
Fortive（FTV）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Fortive的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），Revvity净利率更高（12.7% vs 5.4%，领先7.4%），Revvity同比增速更快（5.9% vs -33.1%），Revvity自由现金流更多（$161.8M vs $153.1M），过去两年Revvity的营收复合增速更高（9.0% vs -19.5%）
Fortive是总部位于美国华盛顿州埃弗里特的工业科技集团，专注于提供互联工作流解决方案所需的核心技术，研发、生产及销售专业工程类产品、软件与服务，旗下业务分为智能运营解决方案、精密技术、先进医疗解决方案三大战略板块。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
FTV vs RVTY — 直观对比
营收规模更大
FTV
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出38.9%
-33.1%
净利率更高
RVTY
高出7.4%
5.4%
自由现金流更多
RVTY
多$8.7M
$153.1M
两年增速更快
RVTY
近两年复合增速
-19.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $55.0M | $98.4M |
| 毛利率 | 63.2% | — |
| 营业利润率 | 15.5% | 14.5% |
| 净利率 | 5.4% | 12.7% |
| 营收同比 | -33.1% | 5.9% |
| 净利润同比 | -75.2% | 3.9% |
| 每股收益（稀释后） | $0.16 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FTVRVTY
| Q4 25 | — | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.5B | $720.3M | ||
| Q1 25 | $1.5B | $664.8M | ||
| Q4 24 | $1.6B | $729.4M | ||
| Q3 24 | $1.5B | $684.0M | ||
| Q2 24 | $1.6B | $691.7M | ||
| Q1 24 | $1.5B | $649.9M |
净利润FTVRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $55.0M | $46.7M | ||
| Q2 25 | $166.6M | $53.9M | ||
| Q1 25 | $171.9M | $42.2M | ||
| Q4 24 | $208.8M | $94.6M | ||
| Q3 24 | $221.6M | $94.4M | ||
| Q2 24 | $195.1M | $55.4M | ||
| Q1 24 | $207.4M | $26.0M |
毛利率FTVRVTY
| Q4 25 | — | — | ||
| Q3 25 | 63.2% | 53.6% | ||
| Q2 25 | 59.0% | 54.5% | ||
| Q1 25 | 59.8% | 56.5% | ||
| Q4 24 | 60.3% | — | ||
| Q3 24 | 60.0% | 56.3% | ||
| Q2 24 | 59.8% | 55.7% | ||
| Q1 24 | 59.3% | 54.6% |
营业利润率FTVRVTY
| Q4 25 | — | 14.5% | ||
| Q3 25 | 15.5% | 11.7% | ||
| Q2 25 | 14.6% | 12.6% | ||
| Q1 25 | 15.8% | 10.9% | ||
| Q4 24 | 19.0% | 16.3% | ||
| Q3 24 | 19.3% | 14.3% | ||
| Q2 24 | 19.4% | 12.4% | ||
| Q1 24 | 19.8% | 6.8% |
净利率FTVRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 5.4% | 6.7% | ||
| Q2 25 | 11.0% | 7.5% | ||
| Q1 25 | 11.7% | 6.4% | ||
| Q4 24 | 12.9% | 13.0% | ||
| Q3 24 | 14.4% | 13.8% | ||
| Q2 24 | 12.6% | 8.0% | ||
| Q1 24 | 13.6% | 4.0% |
每股收益（稀释后）FTVRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | $0.16 | $0.40 | ||
| Q2 25 | $0.49 | $0.46 | ||
| Q1 25 | $0.50 | $0.35 | ||
| Q4 24 | $0.60 | $0.77 | ||
| Q3 24 | $0.63 | $0.77 | ||
| Q2 24 | $0.55 | $0.45 | ||
| Q1 24 | $0.58 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $430.8M | $919.9M |
| 总债务越低越好 | $3.3B | — |
| 股东权益账面价值 | $6.5B | $7.3B |
| 总资产 | $11.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.51× | — |
8季度趋势，按日历期对齐
现金及短期投资FTVRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | $430.8M | $931.4M | ||
| Q2 25 | $1.8B | $991.8M | ||
| Q1 25 | $892.1M | $1.1B | ||
| Q4 24 | $813.3M | $1.2B | ||
| Q3 24 | $811.3M | $1.2B | ||
| Q2 24 | $644.1M | $2.0B | ||
| Q1 24 | $704.6M | $1.7B |
总债务FTVRVTY
| Q4 25 | — | — | ||
| Q3 25 | $3.3B | — | ||
| Q2 25 | $4.8B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $3.7B | — | ||
| Q3 24 | $3.9B | — | ||
| Q2 24 | $3.8B | — | ||
| Q1 24 | $3.9B | — |
股东权益FTVRVTY
| Q4 25 | — | $7.3B | ||
| Q3 25 | $6.5B | $7.4B | ||
| Q2 25 | $10.4B | $7.6B | ||
| Q1 25 | $10.2B | $7.6B | ||
| Q4 24 | $10.2B | $7.7B | ||
| Q3 24 | $10.6B | $7.9B | ||
| Q2 24 | $10.5B | $7.9B | ||
| Q1 24 | $10.5B | $7.8B |
总资产FTVRVTY
| Q4 25 | — | $12.2B | ||
| Q3 25 | $11.9B | $12.1B | ||
| Q2 25 | $18.2B | $12.4B | ||
| Q1 25 | $17.1B | $12.4B | ||
| Q4 24 | $17.0B | $12.4B | ||
| Q3 24 | $17.5B | $12.8B | ||
| Q2 24 | $17.3B | $13.4B | ||
| Q1 24 | $17.5B | $13.4B |
负债/权益比FTVRVTY
| Q4 25 | — | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.46× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 0.36× | — | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.36× | — | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $164.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $153.1M | $161.8M |
| 自由现金流率自由现金流/营收 | 14.9% | 21.0% |
| 资本支出强度资本支出/营收 | 1.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.99× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $1.1B | $509.4M |
8季度趋势，按日历期对齐
经营现金流FTVRVTY
| Q4 25 | — | $182.0M | ||
| Q3 25 | $164.4M | $138.5M | ||
| Q2 25 | $311.2M | $134.3M | ||
| Q1 25 | $241.7M | $128.2M | ||
| Q4 24 | $502.2M | $174.2M | ||
| Q3 24 | $459.0M | $147.9M | ||
| Q2 24 | $308.9M | $158.6M | ||
| Q1 24 | $256.7M | $147.6M |
自由现金流FTVRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | $153.1M | $120.0M | ||
| Q2 25 | $274.5M | $115.5M | ||
| Q1 25 | $215.0M | $112.2M | ||
| Q4 24 | $465.2M | $149.8M | ||
| Q3 24 | $431.2M | $125.6M | ||
| Q2 24 | $279.7M | $136.6M | ||
| Q1 24 | $230.3M | $129.7M |
自由现金流率FTVRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | 14.9% | 17.2% | ||
| Q2 25 | 18.1% | 16.0% | ||
| Q1 25 | 14.6% | 16.9% | ||
| Q4 24 | 28.7% | 20.5% | ||
| Q3 24 | 28.1% | 18.4% | ||
| Q2 24 | 18.0% | 19.7% | ||
| Q1 24 | 15.1% | 20.0% |
资本支出强度FTVRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | 1.1% | 2.6% | ||
| Q2 25 | 2.4% | 2.6% | ||
| Q1 25 | 1.8% | 2.4% | ||
| Q4 24 | 2.3% | 3.4% | ||
| Q3 24 | 1.8% | 3.3% | ||
| Q2 24 | 1.9% | 3.2% | ||
| Q1 24 | 1.7% | 2.7% |
现金转化率FTVRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | 2.99× | 2.97× | ||
| Q2 25 | 1.87× | 2.49× | ||
| Q1 25 | 1.41× | 3.03× | ||
| Q4 24 | 2.41× | 1.84× | ||
| Q3 24 | 2.07× | 1.57× | ||
| Q2 24 | 1.58× | 2.87× | ||
| Q1 24 | 1.24× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FTV
| Advanced Healthcare Solutions | $328.3M | 32% |
| Industrial Manufacturing | $287.9M | 28% |
| Energy And Infrastructure | $166.7M | 16% |
| Government | $88.0M | 9% |
| Retail | $82.7M | 8% |
| Other Direct End Markets | $79.6M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
